Core exploration in optimization of chemokine receptor CCR4 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 3, 2007, Pages 679-682

  Purandare, Ashok V ^a   Wan, Honghe ^a   Somerville, John E ^a   Burke, Christine ^a   Vaccaro, Wayne ^a   Yang, XiaoXia ^a   McIntyre, Kim W ^a   Poss, Michael A ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antagonist; Asthma; Atopic dermatitis; Chemokine receptor CCR4; MDC; TARC

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR4;

ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; EOSINOPHIL; MALE; MOUSE; NONHUMAN; PNEUMONIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZYL COMPOUNDS; CELL LINE; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDICATORS AND REAGENTS; MICE; OVALBUMIN; PNEUMONIA; QUINOLINES; RECEPTORS, CHEMOKINE; RESPIRATORY HYPERSENSITIVITY; STRUCTURE-ACTIVITY RELATIONSHIP;

MURINAE;

EID: 33846202995     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.091     Document Type: Article

References (25)

1. Rossi D., and Zlotnik A. Annu. Rev. Immunol. 18 (2000) 217
2. Zlontik A., and Yoshie O. Immunity 12 (2000) 121
3. Owen C. Pulm. Pharmacol. Ther. 14 (2001) 193
4. Power C.A., and Proudfoot A.E. Curr. Opin. Pharmacol. 1 (2001) 417
5. Berin M.C. Drug News Perspect. 15 (2002) 10
6. Editorial; Clin. Exp. Allergy 2001, 31, 1809.
7. Lukacs N.W. Nat. Rev. Immunol. 1 (2001) 108
8. Mantovani A., Gray P.A., Damme J.V., and Sozzani S. J. Leukoc. Biol. 68 (2000) 400 and references cited therein
9. Wang Y., Zhang Y., Yang X., Han W., Liu Y., Xu Q., Zhao R., Di C., Song Q., and Ma D. Life Sci. 78 (2006) 614
10. Gonzalo J.A., Pan Y., Lloyd C.M., Jia G.Q., Yu G., Dussault B., Powers C.A., Proudfoot A.E., Coyle A.J., Gearing D., and Gutierrzez-Ramos J.C. J. Immunol. 163 (1999) 403
11. Kawasaki S., Takizawa H., Yoneyama H., Nakayama T., Fujisawa R., Izumizaki M., Imai T., Yoshie O., Homma I., Yamamoto K., and Matsushima K. J. Immunol. 166 (2001) 2055
12. Chvatchko Y., Hoogewerf A.J., Meyer A., Alouani S., Juillard P., Buse R., Conquest F., Proudfoot A.E.I., Wells T.N.C., and Power C.A. J. Exp. Med. 191 (2000) 1755
13. Wakugawa M., Nakamura K., Kakinuma T., and Tamaki K. Drug News Perspect. 15 (2002) 175 and references cited therein
14. Purandare A.V., Gao A., Wan H., Sommerville J.E., Seachord C., Burke C., Vaccaro W., Wityak J., and Poss M.A. Bioorg. Med. Chem. Lett. 15 (2005) 2669
15. Purandare A.V., Wan H., Gao A., Somerville J., Burke C., Vaccaro W., Yang X., McIntyre K.W., and Poss M.A. Bioorg. Med. Chem. Lett. 16 (2006) 204
16. Purandare A.V., and Somerville J.E. Curr. Top. Med. Chem. 6 (2006) 1335 and references cited therein
17. Pitts, W. J.; Watson, A. J.; Dodd, J. H. WO2002088079, 2002.
18. All compounds were characterized by LC-MS and NMR analysis. In addition, the yields were based on weight of pure product unless mentioned otherwise.
19. Breshears S.R., Wang S.S., Bechtolt S.G., and Christensen B.E. J. Am. Chem. Soc. 81 (1959) 3789
20. Dorgan R.J.J., Parrick J., and Hardy C.R. J. Chem. Soc., Perkin Trans. 1 4 (1980) 938
21. Dorn H., and Ozegowski R. J. Prakt. Chem. (Leipzig) 324 (1982) 557
22. Elslager E.F., Hess C., Johnson J., Ortwine D., Chu V., and Werbel L.M. J. Med. Chem. 24 (1981) 127
23. Sanmartin C., Echeverria M., Mendivil B., Cordeu L., Cubedo E., Garcia-Foncillas J., Font M., and Palop J.A. Bioorg. Med. Chem. Lett. 13 (2005) 2031
24. 125I-MDC binding with stably expressed human CCR4 in HEK-293 cells; chemotaxis with CCR4-transfected L1.2 cells; calcium mobilization in CEMS529 cells and cytotoxicity in L1.2 cells) were performed using conditions as described in Ref. 5a and b. The values are reported from average of three repeats.
25. OVA lung inflammation model in mice was carried out as described in Ref. 5b.